PolyPid Ltd. (NASDAQ: PYPD) reported its fourth‑quarter and full‑year 2025 results on February 11, 2026. The company posted a quarterly loss of $0.41 per share, missing the consensus estimate of $0.33–$0.34 per share by roughly 21–24%. Revenue for the quarter was $0.0 million, in line with analyst expectations and reflecting the company’s status as a pre‑revenue, late‑stage development firm.
The loss widened compared with the same period a year earlier. In Q4 2025 PolyPid recorded a net loss of $8.5 million, identical to the $8.5 million loss reported in Q4 2024, while the loss per share fell from $1.13 to $0.41. The full‑year 2025 loss of $34.2 million was higher than the $29.0 million loss in 2024, driven by increased research and development and general and administrative expenses. R&D spending fell in the quarter after the completion of the SHIELD II Phase 3 trial, but overall R&D and G&A costs rose for the year as the company accelerated its regulatory and commercial preparation activities.
Cash, cash equivalents, and short‑term deposits stood at $12.9 million as of December 31, 2025, a decline from the $29.5 million reported at the end of June 2025. The June warrant exercise of $26.7 million had previously extended the company’s runway, and an additional $3.7 million was raised from subsequent warrant exercises, providing a modest boost to the year‑end balance. The cash position, while lower than the mid‑year figure, still supports the company’s planned regulatory milestones through the second half of 2026.
PolyPid reiterated its full‑year guidance, maintaining a net loss outlook and confirming that it is on track to submit a rolling NDA for its lead candidate, D‑PLEX100, to the FDA by the end of Q1 2026. The company also highlighted ongoing discussions with potential U.S. commercial partners, positioning D‑PLEX100 for eventual market entry in the surgical site infection prevention space, a market that could exceed $12 million in U.S. revenue potential. The regulatory progress and partnership talks are viewed as the primary catalysts for investor interest, outweighing the earnings miss.
CEO Dikla Czaczkes Akselbrad emphasized that 2026 could be a transformative year, marking the transition from late‑stage development to full commercial execution. COO Ori Warshavsky noted that the Kynatrix technology platform will enhance controlled‑release capabilities across future product candidates, underscoring the company’s broader pipeline strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.